Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen (AMGN) delivered Q1 2026 earnings that beat expectations, with revenue of $8.62 billion and adjusted EPS (earnings per share) of $5.15, offsetting patent losses through growth drivers.
- Pfizer (PFE) offers a higher dividend yield of 6.53%, compared to AMGN's 3.06%, attracting income-oriented investors.
- Year-to-date (YTD), PFE has gained approximately 7%, outperforming AMGN's roughly 1% return, amid recent market volatility.
- Both exhibit low beta values—AMGN at 0.44 and PFE at 0.31—indicating defensive positioning with reduced market sensitivity.
- Analyst average price targets point to potential upside: $353 for AMGN (from ~$330) and $29 for PFE (from ~$26).
- AMGN's forward PE ratio (price-to-earnings) of 14.75 suggests growth expectations, while PFE's 8.98 reflects value amid pipeline catalysts.
Introduction
Amgen (AMGN) and Pfizer (PFE), two pillars of the pharmaceutical industry, offer distinct profiles for investors navigating healthcare sector dynamics. AMGN emphasizes biotechnology innovation in areas like oncology and emerging obesity therapies, while PFE provides broad exposure to vaccines, oncology, and established drugs. This comparison is particularly relevant for traders seeking relative performance insights amid recent earnings cycles and dividend announcements, and for long-term investors balancing growth potential against income stability in a market favoring defensive plays. Key metrics reveal trade-offs in valuation, momentum, and risk, aiding informed positioning.
AMGN Overview and Recent Performance
Amgen Inc. is a biotechnology leader focused on human therapeutics, with key franchises in oncology, inflammation, and cardiovascular diseases, alongside pipeline advancements in obesity. In recent weeks, AMGN shares traded around $330, reflecting a market capitalization (market cap) of approximately $178 billion. The stock experienced a post-earnings pullback despite Q1 2026 results exceeding forecasts—revenue rose to $8.62 billion, adjusted EPS hit $5.15, and 16 products posted double-digit growth. Sentiment has been influenced by robust pipeline updates, including obesity drug MariTide progress and a dividend hike to $2.52 (ex-date May 15, 2026), though tax risks and competition tempered gains. YTD performance stands at about 1%, with a trailing PE ratio of 22.94 and beta of 0.44 signaling relative stability.
PFE Overview and Recent Performance
Pfizer Inc. operates as a global biopharmaceutical firm with diverse offerings in oncology, immunology, vaccines, and rare diseases. Recently, PFE shares hovered near $26, with a market cap of about $150 billion. Performance has shown resilience, with YTD gains around 7% and a one-month decline of roughly 5%, amid broader sector pressures. Key influences include anticipation of pipeline catalysts like FDA approvals for partnered drugs and a sturdy dividend of $0.43 (yield 6.53%, ex-date May 8, 2026), though patent expirations pose headwinds. Trading volume remains elevated, beta at 0.31 underscores low volatility, and trailing PE ratio of 19.36 reflects value positioning relative to peers.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top performers from its library of over 350 AI trading bots, which scan thousands of tickers across stocks, ETFs, and crypto using diverse strategies like technical and fundamental analysis. Only the most suitable for prevailing market conditions—such as volatility in semiconductors or small caps—earn a spot among the 25 featured agents. Stats showcase impressive ranges: annualized returns from +23% to +163%, win rates of 51% to 88%, profit factors up to 7.12, and average trade durations from hours to weeks, with max drawdowns managed via risk controls. These bots vary in timeframe (short-term scalps to swings) and focus (e.g., NVDA semiconductors at +69% annualized or space stocks at +127%), enabling tailored copy trading. Explore them to align with your risk profile and market outlook.
Head-to-Head Comparison
Both AMGN and PFE anchor the pharma sector but diverge in business models: AMGN's biotech emphasis drives innovation in high-growth areas like obesity and oncology, contrasting PFE's diversified portfolio bolstered by vaccines and M&A (mergers and acquisitions). Growth drivers favor AMGN's pipeline momentum, including MariTide, over PFE's post-COVID stabilization and combo therapies. Recent momentum shows PFE's superior YTD edge, yet AMGN's earnings beat signals rebound potential. Risk factors include patent cliffs for both, with PFE more exposed; sector exposure is shared in healthcare defensives. Market sentiment tilts positive for AMGN's execution amid analysts' upside targets, while PFE appeals via yield and value metrics like lower forward PE.
Tickeron AI Verdict
Tickeron's AI currently favors AMGN over PFE, based on stronger trend consistency from recent earnings outperformance, pipeline catalysts in obesity, and relative stability despite volatility. AMGN's growth offsetting patent risks positions it probabilistically ahead in the near term, though PFE's yield and valuation offer compelling counterbalance for conservative strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 5 bullish, 2 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +3.80% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.53% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.22%. For the same industry, the average monthly price growth was +2.11%, and the average quarterly price growth was +2.84%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.22% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | PFE | AMGN / PFE | |
| Capitalization | 189B | 148B | 128% |
| EBITDA | 16.7B | 17.2B | 97% |
| Gain YTD | 8.356 | 8.085 | 103% |
| P/E Ratio | 24.33 | 19.88 | 122% |
| Revenue | 37.2B | 63.3B | 59% |
| Total Cash | 12B | 13.1B | 92% |
| Total Debt | 57.3B | 63.7B | 90% |
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 24 | 100 | |
SMR RATING 1..100 | 12 | 78 | |
PRICE GROWTH RATING 1..100 | 49 | 51 | |
P/E GROWTH RATING 1..100 | 60 | 33 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as AMGN (6) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (24) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for PFE (78) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (49) in the Biotechnology industry is in the same range as PFE (51) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (33) in the Pharmaceuticals Major industry is in the same range as AMGN (60) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | N/A |
| Stochastic ODDS (%) | 2 days ago 40% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 54% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 56% | 2 days ago 56% |
| Declines ODDS (%) | 5 days ago 52% | 4 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 59% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 59% |
Advertisement